Streetbeat News

Stock Prices

AMST

ATXI

BOF

EVO

ISUN

RILY

T

U.S. stocks saw a slight decline with the S&P 500, Dow, and NASDAQ all falling. AT&T reported a slight revenue decrease but beat EPS estimates. BranchOut Food, Amesite, and B. Riley Financial shares surged following positive company news, while Evotec, Avenue Therapeutics, and iSun shares plummeted. Oil and gold prices fell, while copper and silver also saw declines.

Portfolio Pulse from Avi Kapoor

April 24, 2024 | 6:33 pm

BAC

Deep-pocketed investors have shown a bullish sentiment towards Bank of America (NYSE:BAC), with a significant surge in options activity reported by Benzinga. The activity includes 35 notable options trades, with a bullish majority of 54% and a bearish minority of 42%. The trades span a price target window from $20.0 to $40.0 for BAC. The largest trades observed include both calls and puts, with sentiments ranging from neutral to bullish and bearish. Bank of America, a major US financial institution, saw its stock price at $38.06, down by -0.81%, with a trading volume of 16,643,380 and an RSI indicating a potential approach to overbought territory.

Portfolio Pulse from Benzinga Insights

April 24, 2024 | 6:32 pm

AMGN

CGEM

Cullinan Therapeutics Inc's stock is trading higher due to positive implications from an academic case study on Amgen Inc's Blincyto for treating severe systemic sclerosis, which supports Cullinan's expansion into autoimmune diseases with its similar therapy, CLN-978. The company plans to target systemic lupus erythematosus (SLE) first, with a Phase 1 submission expected in Q3. William Blair rates Cullinan shares as Outperform, highlighting the potential of its diverse portfolio, including CLN-619 for cancer and CLN-978 for autoimmune diseases, with a fair share value of $33. Key catalysts include updated data for CLN-619 and CLN-978 expected in 2024.

Portfolio Pulse from Vandana Singh

April 24, 2024 | 6:29 pm

NFLX

TKO

Netflix Inc (NASDAQ: NFLX) is set to air a live comedy roast of Tom Brady, titled 'The Greatest Roast of All Time: Tom Brady,' on May 5, marking its first live roast event. This event is part of Netflix's broader strategy to expand into sports and live content, following the success of sports-adjacent docuseries and live specials. The company has also ventured into live sports specials, a live comedy special, and recently signed a deal with World Wrestling Entertainment, a unit of TKO Group Holdings (NYSE: TKO), to enhance its sports content library.

Portfolio Pulse from Chris Katje

April 24, 2024 | 6:24 pm

BIIB

ESALY

Leqembi, an Alzheimer's drug developed by Eisai Limited (OTC:ESALY) and Biogen Inc (NASDAQ:BIIB), is experiencing slow adoption nine months post-U.S. launch due to skepticism among doctors about its efficacy, costs, and risks. Despite FDA approval and showing a 27% slowdown in cognition decline, less than half of U.S. neurologists recommend it, citing limited patient benefit and significant risks, including potential brain swelling and bleeding. The drug's high cost and the need for regular MRIs and bi-monthly infusions add to the concerns. Eisai and Biogen aim to increase their sales force by 30% to reach 100,000 patients by 2026, despite only a couple thousand patients starting treatment as of January.

Portfolio Pulse from Vandana Singh

April 24, 2024 | 6:23 pm

V

Visa Inc (NYSE:V) reported a fiscal second quarter earnings beat with a share price increase of 0.86% to $276.47. Analysts from Goldman Sachs, Oppenheimer, Wedbush, BMO Capital Markets, Keefe Bruyette & Woods, and Mizuho Securities provided positive outlooks, with adjustments to price targets and reaffirmations of ratings. The earnings beat was attributed to solid revenue trends, strong consulting and marketing services revenue, and resilient cross-border trends. Despite softer trends in April due to Easter timing and lowered volume guidance in the APAC region, expectations for improving ticket sizes in the US and the rest of the world remain. Visa's full-year guidance was reiterated, reflecting confidence in achieving low double-digit top-line growth and earnings growth in the low teens.

Portfolio Pulse from Priya Nigam

April 24, 2024 | 6:22 pm

TXRH

Citigroup analyst Jon Tower has maintained a Buy rating on Texas Roadhouse (NASDAQ:TXRH) and increased the price target from $162 to $178, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 6:21 pm

GM

RBC Capital analyst Tom Narayan has maintained an Outperform rating on General Motors (NYSE:GM) and increased the price target from $56 to $58.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 6:18 pm

HUM

Humana Inc (NYSE:HUM) withdrew its 2025 profit forecast due to lower than expected Medicare Advantage reimbursement rates and a rise in medical benefit ratio to 88.9% in Q1. The company had previously lowered its 2025 Adjusted EPS growth target from $37 to $6-$10, but now finds even this revised target unachievable. Humana will provide more specific 2025 guidance later this year after finalizing pricing decisions for the 2025 Medicare Advantage bids.

Portfolio Pulse from Vandana Singh

April 24, 2024 | 6:18 pm

CRM

Salesforce (NYSE:CRM) has seen significant options trading activity, with a mix of bullish and bearish sentiments among investors. The trading volume and open interest analysis indicate a price target range between $200 and $410. Notable trades include both calls and puts with varying sentiments and strike prices. Salesforce's current trading volume is 1,846,367, with a slight price increase of 0.26% to $277.41. Analyst ratings over the past month suggest an average target price of $351, with ratings ranging from Buy to Outperform. The company is expected to announce earnings in 35 days.

Portfolio Pulse from Benzinga Insights

April 24, 2024 | 6:16 pm